Render Target: STATIC
Render Timestamp: 2024-11-22T11:35:15.988Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-09-30 01:57:37.157
Product last modified at: 2024-10-24T17:30:09.538Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

LOXL2 (E3P7Y) Rabbit mAb #99680

Filter:
  • WB
  • IHC

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 100
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IHC-Immunohistochemistry 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    IHC Leica Bond 1:400 - 1:1600
    Immunohistochemistry (Paraffin) 1:800 - 1:3200

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    For a carrier free (BSA and azide free) version of this product see product #72903.

    Protocol

    Specificity / Sensitivity

    LOXL2 (E3P7Y) Rabbit mAb recognizes endogenous levels of total LOXL2 protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human LOXL2 protein.

    Background

    Lysyl oxidase-like 2 (LOXL2) is a secreted copper-dependent amine oxidase and a member of the lysyl oxidase family (1). It primarily catalyzes the oxidation of lysine (or hydroxylysine) residues in collagen and elastin to form peptidyl aldehyde derivatives (1). These modifications are required for further cross-linking of target proteins to enhance extracellular matrix (ECM) stiffness. LOXL2 has been associated with progression and metastases of many cancer types, including breast cancer and fibrotic disease, all through active remodeling of the ECM (2-5). Additionally, within the cell, LOXL2 has been shown to play a role in EMT, cell polarity, and transcriptional repression (6-8). LOXL2 has become an attractive target for therapeutic intervention in cancer treating, blocking metastasis, and halting fibrosis (9-10).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    SignalStain is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.